US 11,932,668 B2
Selective recovery
Benjamin E. Deverman, Pasadena, CA (US); Paul H. Patterson, Altadena, CA (US); and Viviana Gradinaru, La Cañada Flintridge, CA (US)
Assigned to California Institute of Technology, Pasadena, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US)
Filed on Aug. 13, 2021, as Appl. No. 17/402,317.
Application 17/402,317 is a continuation of application No. 16/680,402, filed on Nov. 11, 2019, granted, now 11,117,933.
Application 16/680,402 is a continuation of application No. 16/222,549, filed on Dec. 17, 2018, granted, now 10,519,198, issued on Dec. 31, 2019.
Application 16/222,549 is a continuation of application No. 15/926,892, filed on Mar. 20, 2018, granted, now 10,202,425, issued on Feb. 12, 2019.
Application 15/926,892 is a continuation of application No. 15/422,237, filed on Feb. 1, 2017, granted, now 9,957,303, issued on May 1, 2018.
Application 15/422,237 is a continuation of application No. 14/485,024, filed on Sep. 12, 2014, granted, now 9,585,971, issued on Mar. 7, 2017.
Claims priority of provisional application 62/034,060, filed on Aug. 6, 2014.
Claims priority of provisional application 62/020,658, filed on Jul. 3, 2014.
Claims priority of provisional application 61/983,624, filed on Apr. 24, 2014.
Claims priority of provisional application 61/877,506, filed on Sep. 13, 2013.
Prior Publication US 2022/0098243 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 38/47 (2006.01); A61K 38/48 (2006.01); A61K 38/50 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); C07K 7/06 (2006.01); C12N 7/00 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 38/1709 (2013.01); A61K 38/2093 (2013.01); A61K 38/47 (2013.01); A61K 38/4813 (2013.01); A61K 38/50 (2013.01); A61K 39/3955 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); C07K 7/06 (2013.01); C12N 7/00 (2013.01); C12N 15/1068 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C07K 2319/33 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14145 (2013.01); C12N 2810/6027 (2013.01); C12Y 304/14009 (2013.01); C12Y 305/01015 (2013.01)] 18 Claims
 
1. A method of delivering a nucleic acid sequence to a nervous system of a subject, the method comprising:
providing a targeting peptide comprising at least 4 contiguous amino acids from an amino acid sequence of TLAVPFK (SEQ ID NO: 1) or a targeting peptide comprising at least 6 contiguous amino acids from an amino acid sequence selected from the group consisting of ILGTGTS (SEQ ID NO: 55), TRTNPEA (SEQ ID NO: 56), NGGTSSS (SEQ ID NO: 58), and YTLSQGW (SEQ ID NO: 60), wherein the targeting peptide is part of a capsid of an AAV vector comprising a nucleic acid sequence to be delivered to the nervous system, and wherein the targeting peptide is inserted between two amino acids in the capsid amino acid sequence of the AAV vector which correspond to AA588-589 or AA452-458 of SEQ ID NO: 2; and
administering the AAV vector to the subject.